Sie sind auf Seite 1von 3

How does it work?

This injection contains a medicine called human anti-D immunoglobulin. It is given to pregnant women who have a blood type known as rhesus negative. People whose blood type is rhesus positive (RhD positive) have a substance called D antigen on the surface of their red blood cells. People whose blood type is rhesus negative (RhD negative) are missing this antigen. Whether a person is rhesus positive or rhesus negative is determined by their genes. Having a rhesus negative blood type is not usually a problem. However, if a rhesus negative woman is pregnant and her baby is rhesus positive it may cause problems. If blood cells from a rhesus positive baby get into the rhesus negative mother's bloodstream, her blood will react as if the babys blood is a foreign substance and will produce antibodies against it. This is not usually a problem in a first pregnancy with a rhesus positive baby. However, the antibodies that the mother produces stay in her blood, and if she has another pregnancy with a baby who is also rhesus positive, her antibodies can cross the placenta and attack the blood cells of the unborn baby. This can cause 'haemolytic disease of the newborn'. Haemolytic disease of the newborn can be very mild, but in a small number of babies it can be more serious and cause the baby to be stillborn, severely disabled or to die after birth as a result of anaemia and jaundice. The most common time for a baby's blood cells to get into the mother's blood, causing her to produce antibodies, is at the time of birth. However, this can also occur at other times, for example during a miscarriage or abortion, or as the result of having an amniocentesis, chorionic villus sampling, vaginal bleeding, or turning the babys head down (external cephalic version). These events are called 'potentially sensitising events'. To prevent rhesus negative women producing antibodies against their babys blood during pregnancy they can be given an injection with anti-D immunoglobulin. This treatment is called anti-D prophylaxis, and prevents the mother's immune reaction that could cause haemolytic disease of the newborn. Anti-D prophylaxis is offered routinely to pregnant women who are rhesus negative, usually at weeks 28 and 34 of their pregnancy, unless they already have anti-D antibodies in their blood. (This is tested by a blood test at the start of the pregnancy.) The treatment is offered regardless of whether a sensitisation event has occurred, in order to be absolutely certain that the mother does not develop antibodies against the baby. After the birth, a blood sample will be taken to test the baby's blood group. If the baby is rhesus positive, the mother will be given a further injection of anti-D immunoglobulin. (This is called postnatal anti-D prophylaxis.) Anti-D immunoglobulin will also given after any sensitising event that occurs during the pregnancy.

Anti-D prophylaxis may not be necessary for rhesus negative mothers if there is certainty that she will not have another child following the pregnancy, for example if she is to be sterilised after the birth. It will also not be necessary if the father's blood type is also rhesus negative, as genetically this means the baby cannot be rhesus positive. Anti-D immunoglobulin may also be used if a rhesus negative individual is given a blood transfusion of rhesus positive blood, to prevent the individual forming antibodies against the transfused blood.

What is it used for?


Preventing pregnant women whose blood type is rhesus negative from forming antibodies against their rhesus positive baby Preventing rhesus negative individuals who have received a rhesus positive blood transfusion from forming antibodies against the blood

Warning!

You should be monitored for at least 20 minutes after receiving this injection, as in very rare cases an allergic reaction can occur. Tell your doctor if you experience any symptoms of an allergic reaction, for example skin reactions such as hives or itching, shortness of breath, wheezing, or feeling dizzy.

Use with caution in


People who have antibodies against immunoglobulin A (IgA) People who have had atypical reactions following receipt of a blood transfusion or blood products

Not to be used in

Individuals whose blood type is rhesus (RhD) positive

This medicine should not be used if you are allergic to one or any of its ingredients. Please inform your doctor or pharmacist if you have previously experienced such an allergy. If you feel you have experienced an allergic reaction, stop using this medicine and inform your doctor or pharmacist immediately.

Pregnancy and Breastfeeding

Certain medicines should not be used during pregnancy or breastfeeding. However, other medicines may be safely used in pregnancy or breastfeeding providing the benefits to the mother outweigh the risks to the unborn baby. Always inform your doctor if you are pregnant or planning a pregnancy, before using any medicine.

There are no known harmful effects when this medicine is used during pregnancy. There are no known harmful effects when this medicine is used by breastfeeding mothers.

Side effects
Medicines and their possible side effects can affect individual people in different ways. The following are some of the side effects that are known to be associated with this medicine. Because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect.

Headache Fever (pyrexia) Skin reactions such as rash and itch A general feeling of being unwell (malaise) Pain, soreness or bruising at the injection site

The side effects listed above may not include all of the side effects reported by the drug's manufacturer. For more information about any other possible risks associated with this medicine, please read the information provided with the medicine or consult your doctor or pharmacist.

How can this medicine affect other medicines?


People who have received anti-D immunoglobulin should not receive the measles, mumps and rubella (MMR) vaccine within the following three months, as the efficacy of this vaccine may be reduced if it is administered during this period. If you need to be given anti-D immunoglobulin within two to four weeks of receiving a live vaccine, such as yellow fever, rubella, BCG or oral polio, the anti-D immunoglobulin may reduce the efficacy of these vaccines. Discuss this with your doctor.

Das könnte Ihnen auch gefallen